The New Frontier: Ibogaine in 2026 As we navigate 2026, the global perception of ibogaine has shifted from a fringe alternative to a serious subject of rigorous scientific inquiry. Once sidelined by its classification as a Schedule I substance, ibogaine is now at the center of a federal push to expand research into psychedelic-assisted therapies. […]
For decades, mental health disorders such as depression, anxiety, PTSD, and addiction have been treated using conventional pharmaceuticals. However, while medications like SSRIs and benzodiazepines can help manage symptoms, they often come with serious side effects, high dependency risks, and limited long-term efficacy. A new frontier in mental health treatment is emerging—psilocybin therapy, derived from […]